A number of other research firms also recently issued reports on NCNA. William Blair restated an “outperform” rating on shares of NuCana in a research report on Thursday, May 16th. Zacks Investment Research upgraded shares of NuCana from a “sell” rating to a “hold” rating in a research report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $25.50.
Shares of NuCana stock traded down $0.31 during trading hours on Wednesday, reaching $8.47. The company’s stock had a trading volume of 2,560 shares, compared to its average volume of 12,758. The business’s 50 day moving average price is $10.09. NuCana has a one year low of $7.53 and a one year high of $30.10. The stock has a market capitalization of $290.03 million, a PE ratio of -14.80 and a beta of 3.29.
Institutional investors have recently bought and sold shares of the company. Rothschild Investment Corp IL acquired a new position in NuCana during the first quarter worth approximately $211,000. Alps Advisors Inc. increased its position in shares of NuCana by 5.6% in the first quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock worth $1,323,000 after acquiring an additional 4,160 shares in the last quarter. Asymmetry Capital Management L.P. increased its position in shares of NuCana by 5.4% in the first quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after acquiring an additional 2,346 shares in the last quarter. Marshall Wace North America L.P. increased its position in shares of NuCana by 558.8% in the first quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after acquiring an additional 51,607 shares in the last quarter. Finally, Aperio Group LLC acquired a new stake in shares of NuCana in the second quarter worth $39,000. Institutional investors own 38.08% of the company’s stock.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.
Further Reading: How mutual funds make money
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.